Iraq

Iraq

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
1.98 (1.62 - 2.31) 2019 Modelled IHME
2.09 (1.75 - 2.44) 2018 Modelled IHME
2.15 (1.80 - 2.54) 2017 Modelled IHME
2.15 (1.80 - 2.50) 2016 Modelled IHME
2.15 (1.79 - 2.48) 2015 Modelled IHME
2.18 (1.82 - 2.51) 2014 Modelled IHME
2.25 (1.88 - 2.59) 2013 Modelled IHME
2.34 (1.94 - 2.71) 2012 Modelled IHME
2.43 (1.98 - 2.84) 2011 Modelled IHME
2.5 (2.02 - 2.97) 2010 Modelled IHME
2.56 (2.06 - 3.03) 2009 Modelled IHME
2.61 (2.10 - 3.09) 2008 Modelled IHME
2.66 (2.15 - 3.15) 2007 Modelled IHME
2.72 (2.21 - 3.23) 2006 Modelled IHME
2.77 (2.25 - 3.32) 2005 Modelled IHME
2.84 (2.29 - 3.35) 2004 Modelled IHME
2.9 (2.35 - 3.43) 2003 Modelled IHME
2.97 (2.38 - 3.50) 2002 Modelled IHME
3.04 (2.43 - 3.60) 2001 Modelled IHME
3.11 (2.48 - 3.68) 2000 Modelled IHME
3.19 (2.55 - 3.78) 1999 Modelled IHME
3.27 (2.63 - 3.87) 1998 Modelled IHME
3.36 (2.71 - 3.98) 1997 Modelled IHME
3.45 (2.79 - 4.10) 1996 Modelled IHME
3.52 (2.84 - 4.23) 1995 Modelled IHME
3.58 (2.91 - 4.28) 1994 Modelled IHME
3.64 (2.98 - 4.36) 1993 Modelled IHME
3.7 (3.04 - 4.41) 1992 Modelled IHME
3.74 (3.09 - 4.50) 1991 Modelled IHME
3.79 (3.13 - 4.56) 1990 Modelled IHME
0.14 (0.11 - 0.18) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.43 (0.31 - 0.56) 2019 Modelled IHME
0.62 (0.46 - 0.80) 2018 Modelled IHME
0.74 (0.55 - 0.96) 2017 Modelled IHME
0.8 (0.60 - 1.02) 2016 Modelled IHME
0.82 (0.62 - 1.06) 2015 Modelled IHME
0.81 (0.62 - 1.05) 2014 Modelled IHME
0.79 (0.60 - 1.02) 2013 Modelled IHME
0.77 (0.58 - 1) 2012 Modelled IHME
0.75 (0.56 - 0.97) 2011 Modelled IHME
0.74 (0.55 - 0.97) 2010 Modelled IHME
0.77 (0.56 - 1) 2009 Modelled IHME
0.82 (0.60 - 1.07) 2008 Modelled IHME
0.9 (0.66 - 1.16) 2007 Modelled IHME
0.97 (0.71 - 1.25) 2006 Modelled IHME
1.04 (0.75 - 1.34) 2005 Modelled IHME
1.09 (0.79 - 1.40) 2004 Modelled IHME
1.13 (0.83 - 1.45) 2003 Modelled IHME
1.18 (0.87 - 1.51) 2002 Modelled IHME
1.23 (0.92 - 1.57) 2001 Modelled IHME
1.3 (0.97 - 1.68) 2000 Modelled IHME
1.41 (1.05 - 1.82) 1999 Modelled IHME
1.57 (1.17 - 2.01) 1998 Modelled IHME
1.74 (1.29 - 2.22) 1997 Modelled IHME
1.88 (1.38 - 2.41) 1996 Modelled IHME
1.94 (1.41 - 2.52) 1995 Modelled IHME
1.96 (1.44 - 2.53) 1994 Modelled IHME
1.97 (1.47 - 2.55) 1993 Modelled IHME
1.98 (1.48 - 2.58) 1992 Modelled IHME
1.99 (1.48 - 2.60) 1991 Modelled IHME
1.99 (1.48 - 2.63) 1990 Modelled IHME
0.06 (0.04 - 0.08) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
36 (28 - 46) 2019 Modelled IHME
37 (28 - 46) 2018 Modelled IHME
37 (29 - 46) 2017 Modelled IHME
37 (29 - 46) 2016 Modelled IHME
37 (29 - 46) 2015 Modelled IHME
37 (29 - 46) 2014 Modelled IHME
37 (29 - 46) 2013 Modelled IHME
37 (29 - 47) 2012 Modelled IHME
37 (30 - 47) 2011 Modelled IHME
38 (30 - 47) 2010 Modelled IHME
38 (30 - 47) 2009 Modelled IHME
38 (30 - 47) 2008 Modelled IHME
38 (31 - 47) 2007 Modelled IHME
39 (31 - 48) 2006 Modelled IHME
39 (31 - 48) 2005 Modelled IHME
39 (31 - 48) 2004 Modelled IHME
39 (31 - 48) 2003 Modelled IHME
39 (31 - 48) 2002 Modelled IHME
38 (31 - 48) 2001 Modelled IHME
38 (31 - 48) 2000 Modelled IHME
38 (30 - 48) 1999 Modelled IHME
38 (31 - 48) 1998 Modelled IHME
38 (30 - 49) 1997 Modelled IHME
38 (30 - 48) 1996 Modelled IHME
38 (30 - 48) 1995 Modelled IHME
38 (30 - 48) 1994 Modelled IHME
38 (30 - 47) 1993 Modelled IHME
38 (30 - 48) 1992 Modelled IHME
37 (29 - 47) 1991 Modelled IHME
37 (29 - 47) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
41 2018 Survey/reported WHO/UNICEF
44 2017 Survey/reported WHO/UNICEF
47 2016 Survey/reported WHO/UNICEF
43 2015 Survey/reported WHO/UNICEF
43 2014 Survey/reported WHO/UNICEF
43 2013 Survey/reported WHO/UNICEF
37 2012 Survey/reported WHO/UNICEF
32 2011 Survey/reported WHO/UNICEF
27 2010 Survey/reported WHO/UNICEF
60 2009 Survey/reported WHO/UNICEF
92 2008 Survey/reported WHO/UNICEF
90 2007 Survey/reported WHO/UNICEF
88 2006 Survey/reported WHO/UNICEF
93 2005 Survey/reported WHO/UNICEF
92 2004 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
84 2018 Survey/reported WHO/UNICEF
85 2017 Survey/reported WHO/UNICEF
73 2016 Survey/reported WHO/UNICEF
68 2015 Survey/reported WHO/UNICEF
69 2014 Survey/reported WHO/UNICEF
68 2013 Survey/reported WHO/UNICEF
62 2012 Survey/reported WHO/UNICEF
78 2011 Survey/reported WHO/UNICEF
72 2010 Survey/reported WHO/UNICEF
75 2009 Survey/reported WHO/UNICEF
66 2008 Survey/reported WHO/UNICEF
56 2007 Survey/reported WHO/UNICEF
59 2006 Survey/reported WHO/UNICEF
65 2005 Survey/reported WHO/UNICEF
62 2004 Survey/reported WHO/UNICEF
63 2003 Survey/reported WHO/UNICEF
65 2002 Survey/reported WHO/UNICEF
66 2001 Survey/reported WHO/UNICEF
67 2000 Survey/reported WHO/UNICEF
52 1999 Survey/reported WHO/UNICEF
3 1998 Survey/reported WHO/UNICEF
65 1997 Survey/reported WHO/UNICEF
22 1996 Survey/reported WHO/UNICEF
57 1995 Survey/reported WHO/UNICEF
40 1994 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2017
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2004
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.09 (0.88 - 1.36) 2019 Modelled IHME
1.08 (0.87 - 1.35) 2018 Modelled IHME
1.08 (0.87 - 1.35) 2017 Modelled IHME
1.13 (0.92 - 1.38) 2016 Modelled IHME
1.18 (0.96 - 1.43) 2015 Modelled IHME
1.14 (0.93 - 1.38) 2014 Modelled IHME
1.04 (0.86 - 1.26) 2013 Modelled IHME
0.93 (0.76 - 1.11) 2012 Modelled IHME
0.83 (0.68 - 1) 2011 Modelled IHME
0.79 (0.65 - 0.96) 2010 Modelled IHME
0.79 (0.65 - 0.96) 2009 Modelled IHME
0.79 (0.65 - 0.96) 2008 Modelled IHME
0.8 (0.65 - 0.97) 2007 Modelled IHME
0.8 (0.65 - 0.97) 2006 Modelled IHME
0.8 (0.65 - 0.97) 2005 Modelled IHME
0.8 (0.65 - 0.97) 2004 Modelled IHME
0.79 (0.64 - 0.96) 2003 Modelled IHME
0.78 (0.63 - 0.95) 2002 Modelled IHME
0.77 (0.63 - 0.94) 2001 Modelled IHME
0.77 (0.62 - 0.94) 2000 Modelled IHME
0.8 (0.65 - 0.98) 1999 Modelled IHME
0.89 (0.72 - 1.09) 1998 Modelled IHME
1 (0.81 - 1.23) 1997 Modelled IHME
1.09 (0.88 - 1.35) 1996 Modelled IHME
1.14 (0.91 - 1.41) 1995 Modelled IHME
1.16 (0.93 - 1.44) 1994 Modelled IHME
1.18 (0.94 - 1.46) 1993 Modelled IHME
1.19 (0.95 - 1.48) 1992 Modelled IHME
1.2 (0.96 - 1.49) 1991 Modelled IHME
1.2 (0.96 - 1.50) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
3.2 (0.30 - 3.20) 2014 Modelled Gower et al, 2014

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
36 (27 - 45) 2019 Modelled IHME
36 (26 - 44) 2018 Modelled IHME
35 (26 - 44) 2017 Modelled IHME
35 (26 - 44) 2016 Modelled IHME
36 (27 - 44) 2015 Modelled IHME
36 (27 - 44) 2014 Modelled IHME
36 (27 - 44) 2013 Modelled IHME
35 (27 - 44) 2012 Modelled IHME
35 (27 - 44) 2011 Modelled IHME
35 (27 - 44) 2010 Modelled IHME
35 (27 - 43) 2009 Modelled IHME
35 (26 - 43) 2008 Modelled IHME
34 (26 - 43) 2007 Modelled IHME
34 (26 - 42) 2006 Modelled IHME
34 (26 - 42) 2005 Modelled IHME
34 (26 - 42) 2004 Modelled IHME
34 (26 - 42) 2003 Modelled IHME
34 (26 - 42) 2002 Modelled IHME
34 (26 - 42) 2001 Modelled IHME
34 (26 - 42) 2000 Modelled IHME
34 (26 - 42) 1999 Modelled IHME
34 (25 - 43) 1998 Modelled IHME
34 (25 - 43) 1997 Modelled IHME
34 (25 - 43) 1996 Modelled IHME
34 (25 - 43) 1995 Modelled IHME
35 (25 - 44) 1994 Modelled IHME
35 (25 - 44) 1993 Modelled IHME
35 (26 - 44) 1992 Modelled IHME
35 (26 - 44) 1991 Modelled IHME
36 (26 - 44) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2017
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2004
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
1.98 (%)
2019
(1.62 - 2.31(%))
IHME
HCV (RNA/cAg+)
1.09 (%)
2019
(0.88 - 1.36(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
1,094
2019
(801 - 1,460)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
1,660
2019
(1,217 - 2,152)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.43 (%)
2019, latest modelled
(0.31 - 0.56(%))
IHME

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
41 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines